Viral and host network analysis of the human cytomegalovirus transcriptome in latency
Abstract
The human cytomegalovirus (HCMV) UL135 and UL138 genes play opposing roles regulating latency and reactivation in CD34 + human progenitor cells. We designed an RNA sequencing study to compare the transcriptional profile of HCMV infection in the presence and absence of these genes using the Tohoku Hospital Pediatrics-1 (THP-1) monocytic cell line model for latency. Relative to primary cell models, THP-1 cells offer the strength of a homogenous population that uniformly silences gene expression and will synchronously reexpress viral genes following stimulation to differentiate, which models early phases of viral reactivation. The loss of UL138 resulted in elevated levels of viral gene expression and in spontaneous adhesion of distinct cell populations that support HCMV gene expression and genome synthesis. The loss of UL135 resulted in diminished viral gene expression during an initial burst that occurs as latency is established and in no expression of eleven viral genes from the UL b ′ region even following differentiation and reexpression of viral genes. Transcriptional network analysis revealed host transcription factors (TFs) with potential to regulate the UL b ′ genes in coordination with pUL135. We show that the cellular TF peroxisome proliferator-activated receptor gamma binds to the viral genome and influences the expression of UL133-UL138 locus genes. Our results define roles for UL135 and UL138 in regulation of patterns of viral gene expression for the establishment of latency and reexpression of viral genes for reactivation and reveal insights into differentiation-linked mechanisms of transcriptional control of the HCMV genome.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Donna Collins-McMillen
Bioscience Innovation Organization Five Disciplines (BIO5) Institute, University of Arizona
Diogo De Oliveira Pessoa
Bioinformatics Shared Resource, Arizona Cancer Center, University of Arizona
Kristen Zarrella
Department of Immunobiology, University of Arizona
Christopher J. Parkins
Vaccine and Gene Therapy Institute, Oregon Health Science University
Michael Daily
Vaccine and Gene Therapy Institute, Oregon Health Science University
David R. McKinzey
Bioscience Innovation Organization Five Disciplines (BIO5) Institute, University of Arizona
Nathaniel J. Moorman
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill
Jeremy P. Kamil
Department of Microbiology and Immunology, Louisiana State University Health Sciences Center
Patrizia Caposio
Vaccine and Gene Therapy Institute, Oregon Health Science University
Megha Padi
Bioinformatics Shared Resource, Arizona Cancer Center, University of Arizona
Felicia D. Goodrum
Bioscience Innovation Organization Five Disciplines (BIO5) Institute, University of Arizona